DURHAM, N.C., July 29 (Bernama-GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through November 5, 2021).
“These results are encouraging as CAB efficacy was sustained during the 12 months following unblinding, confirming a high level of protection against HIV acquisition among study participants assigned female at birth,” said Dr. Sinead Delany-Moretlwe, HPTN 084 protocol chair, director of research at Wits RHI, and research professor at the University of the Witwatersrand in Johannesburg, South Africa.
http://mrem.bernama.com/viewsm.php?idm=43766